These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 29563634)

  • 1. The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.
    Polena H; Creuzet J; Dufies M; Sidibé A; Khalil-Mgharbel A; Salomon A; Deroux A; Quesada JL; Roelants C; Filhol O; Cochet C; Blanc E; Ferlay-Segura C; Borchiellini D; Ferrero JM; Escudier B; Négrier S; Pages G; Vilgrain I
    Br J Cancer; 2018 May; 118(9):1179-1188. PubMed ID: 29563634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for post-translational processing of vascular endothelial (VE)-cadherin in brain tumors: towards a candidate biomarker.
    Vilgrain I; Sidibé A; Polena H; Cand F; Mannic T; Arboleas M; Boccard S; Baudet A; Gulino-Debrac D; Bouillet L; Quesada JL; Mendoza C; Lebas JF; Pelletier L; Berger F
    PLoS One; 2013; 8(12):e80056. PubMed ID: 24358106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib.
    Niinivirta M; Georganaki M; Enblad G; Lindskog C; Dimberg A; Ullenhag GJ
    BMC Cancer; 2020 Apr; 20(1):339. PubMed ID: 32321460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.
    Rautiola J; Lampinen A; Mirtti T; Ristimäki A; Joensuu H; Bono P; Saharinen P
    PLoS One; 2016; 11(4):e0153745. PubMed ID: 27100185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma.
    Dufies M; Nollet M; Ambrosetti D; Traboulsi W; Viotti J; Borchiellini D; Grépin R; Parola J; Giuliano S; Helley-Russick D; Bensalah K; Ravaud A; Bernhard JC; Schiappa R; Bardin N; Dignat-George F; Rioux-Leclercq N; Oudard S; Négrier S; Ferrero JM; Chamorey E; Blot-Chabaud M; Pagès G
    Theranostics; 2018; 8(9):2447-2458. PubMed ID: 29721091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
    Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site.
    Wallez Y; Cand F; Cruzalegui F; Wernstedt C; Souchelnytskyi S; Vilgrain I; Huber P
    Oncogene; 2007 Feb; 26(7):1067-77. PubMed ID: 16909109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.
    Paule B; Bastien L; Deslandes E; Cussenot O; Podgorniak MP; Allory Y; Naïmi B; Porcher R; de La Taille A; Menashi S; Calvo F; Mourah S
    PLoS One; 2010 May; 5(5):e10715. PubMed ID: 20502715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation.
    Lin MT; Yen ML; Lin CY; Kuo ML
    Mol Pharmacol; 2003 Nov; 64(5):1029-36. PubMed ID: 14573751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
    Khella HWZ; Butz H; Ding Q; Rotondo F; Evans KR; Kupchak P; Dharsee M; Latif A; Pasic MD; Lianidou E; Bjarnason GA; Yousef GM
    Mol Ther; 2015 Nov; 23(11):1748-1758. PubMed ID: 26201448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
    D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
    J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
    Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
    Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
    Pilskog M; Bostad L; Edelmann RJ; Akslen LA; Beisland C; Straume O
    J Pathol Clin Res; 2018 Apr; 4(2):114-123. PubMed ID: 29665322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies.
    Bastin J; Werbrouck E; Verbiest A; Punie K; Bechter O; Woei-A-Jin FJ; Wolter P; Wildiers H; Lerut E; Dumez H; Decallonne B; Clement P; Vanderschueren D; Albersen M; Oyen R; Schöffski P; Beuselinck B
    Acta Clin Belg; 2019 Jun; 74(3):169-179. PubMed ID: 29774795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma.
    Trávníček I; Branžovský J; Kalusová K; Hes O; Holubec L; Pele KB; Ürge T; Hora M
    Anticancer Res; 2015 Oct; 35(10):5661-6. PubMed ID: 26408740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma.
    Minardi D; Lucarini G; Santoni M; Mazzucchelli R; Burattini L; Pistelli M; Bianconi M; Di Primio R; Scartozzi M; Montironi R; Cascinu S; Muzzonigro G
    Anticancer Res; 2013 Nov; 33(11):5017-22. PubMed ID: 24222145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma.
    Wang B; Gu W; Wan F; Shi G; Ye D
    Int Braz J Urol; 2019; 45(1):89-99. PubMed ID: 29570259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.